← Back to patent-cliff list
Momelotinib Dihydrochloride
Tier C — Watch / tradeMomelotinib Dihydrochloride
Gilead Sciences Inc
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK2, ACVR1, JAK1
Brand：Omjjara, Ojjaara
Indications (approved)：Myelofibrosis, Myeloproliferative neoplasm, Splenomegaly, Anaemia
Regional status
US
Approved
2023-09-15
EU
Approved
2024-01-25
China
-
Japan
Approved
2024-06-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Momelotinib Dihydrochloride?
Approved indications include: Myelofibrosis, Myeloproliferative neoplasm, Splenomegaly, Anaemia.
When does the Momelotinib Dihydrochloride patent expire?
No public expiry year is available for Momelotinib Dihydrochloride yet; this page updates once verified.
How do I get a quote for Momelotinib Dihydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01